Pfizer reinforced its obesity and diabetes case for berobenatide with new mid-stage results presented at ADA and reported by STAT+. In the VESPER-3 study, patients transitioned from weekly dosing to higher monthly doses, with weight loss continuing through 28 weeks and no plateau yet. Separately, another ADA session-focused report says Pfizer is also “padding the case” for berobenatide in obesity, adding validation for the Metsera acquisition. The company continues to position monthly administration as a practical option versus weekly injectables already competing in the obesity market.